Adjuvant Radiotherapy for Surgically Resected Stage III Merkel Cell Carcinoma

Seyed Saeed Pairawan; Chloe E Dominguez; Naveenraj Solomon; David Caba-Molina; Michael O'Leary; Mark E Reeves; Jukes P Namm

doi:10.1001/jamasurg.2023.7016

Adjuvant Radiotherapy for Surgically Resected Stage III Merkel Cell Carcinoma

JAMA Surg. 2024 Mar 1;159(3):347-349. doi: 10.1001/jamasurg.2023.7016.

Authors

Seyed Saeed Pairawan¹, Chloe E Dominguez², Naveenraj Solomon¹, David Caba-Molina¹, Michael O'Leary¹, Mark E Reeves¹, Jukes P Namm¹

Affiliations

¹ Department of Surgery, Loma Linda University Health, Loma Linda, California.
² Department of Surgery, Swedish Medical Center, Seattle, Washington.

PMID: 38231528
PMCID: PMC10794966 (available on 2025-01-17)
DOI: 10.1001/jamasurg.2023.7016

No abstract available

Plain language summary

This case-control study evaluates whether adjuvant radiotherapy is associated with overall survival among patients with surgically resected stage III Merkel cell carcinoma.

MeSH terms

Carcinoma, Merkel Cell* / pathology
Carcinoma, Merkel Cell* / radiotherapy
Disease-Free Survival
Humans
Neoplasm Staging
Radiotherapy, Adjuvant
Retrospective Studies
Skin Neoplasms* / pathology